Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases... Show more
KNSA saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on December 29, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 46 instances where the indicator turned negative. In of the 46 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
The 10-day RSI Indicator for KNSA moved out of overbought territory on December 23, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on January 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KNSA as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
KNSA moved below its 50-day moving average on January 13, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KNSA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where KNSA advanced for three days, in of 304 cases, the price rose further within the following month. The odds of a continued upward trend are .
KNSA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 171 cases where KNSA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. KNSA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.590) is normal, around the industry mean (29.698). P/E Ratio (87.756) is within average values for comparable stocks, (76.061). KNSA's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.042). KNSA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (5.058) is also within normal values, averaging (72.584).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
a manufacturer of pharmaceutical products
Industry PharmaceuticalsGeneric
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| PHRIX | 18.09 | 0.11 | +0.61% |
| Virtus Duff & Phelps Real Estate Secs I | |||
| IGFAX | 9.28 | -0.01 | -0.11% |
| VY® Morgan Stanley Global Franchise A | |||
| ATWAX | 26.26 | -0.09 | -0.34% |
| AB Tax-Managed Wealth Apprec Strat A | |||
| HIAGX | 23.49 | -0.14 | -0.59% |
| Hartford Disciplined Equity HLS IA | |||
| JDCRX | 43.19 | -0.58 | -1.33% |
| Janus Henderson Forty R | |||
A.I.dvisor indicates that over the last year, KNSA has been loosely correlated with COYA. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if KNSA jumps, then COYA could also see price increases.
| Ticker / NAME | Correlation To KNSA | 1D Price Change % | ||
|---|---|---|---|---|
| KNSA | 100% | +2.49% | ||
| COYA - KNSA | 42% Loosely correlated | +0.43% | ||
| ABVC - KNSA | 40% Loosely correlated | -0.95% | ||
| JBIO - KNSA | 37% Loosely correlated | +6.23% | ||
| AMRN - KNSA | 36% Loosely correlated | -0.99% | ||
| CPRX - KNSA | 36% Loosely correlated | +3.67% | ||
More | ||||
| Ticker / NAME | Correlation To KNSA | 1D Price Change % |
|---|---|---|
| KNSA | 100% | +2.49% |
| Pharmaceuticals: Generic industry (218 stocks) | 35% Loosely correlated | +0.49% |
| Pharmaceuticals industry (383 stocks) | 30% Poorly correlated | +0.34% |